Trial profile The FIELD study investigators, Lancet Published online November 14, 2005.

Slides:

Advertisements

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Advertisements

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

Trial profile Fox K et al. Lancet 2008;372:

Henry C. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.

Effectiveness of interactive web-based lifestyle program on prevention of cardiovascular diseases risk factors in patient with metabolic syndrome: a randomized.

Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.

Henry N. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.

Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.

Slide Source: Lipids Online Slide Library Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

Slide Source: Primary and Other Outcomes: DREAM Rosiglitazone group (n=2635) Placebo group (n=2634)HR (95% CI)p Composite primary.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.

Role of Fenofibrate in Diabetic Dyslipidemia. Diabetic Dyslipidaemia Occurs in type 2 diabetes mellitus High levels of triglycerides Low levels of HDL-C.

Sattar N, et al. Lancet 2010;375: Flow diagram of literature search to identify randomised placebo-controlled and standard care-controlled statin.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

Baseline Characteristics of Individuals From the General Population by Quartiles of Triglyceride Levels a Børge G. Nordestgaard, et al. JAMA 2007;298:

Scandinavian Simvastatin Survival Study (4S) The Lancet, Vol 344, November 19, 1994.

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June.

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.

Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Trial profile Mann JF et al. Lancet 2008;372:

Date of download: 6/3/2016 From: Elevated Plasma Homocysteine Level Is an Independent Predictor of Coronary Heart Disease Events in Patients with Type.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Presented by Slyter Nutrition Consulting Services.

1 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled.

R1. 이정미 / prof. 김우식. INTRODUCTION Reduction in low-density lipoprotein (LDL) cholesterol levels has proved to be highly effective in reducing rates of.

Circulation. 2013;128: R4 이태인 / Prof. 우종신.

Volume 376, Issue 9753, Pages (November 2010)

Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Blood Pressure and Lipid Trials: Rationale, Importance and Design

The SPRINT Research Group

Pravastatin in Elderly Individuals at Risk of Vascular Disease

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Louise Bowman & Martin Landray on.

Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.

SEARCH Collaborative Group. Lancet 2010;epub 9 Nov

AIM HIGH Niacin plus Statin to prevent vascular events

Scandinavian Simvastatin Survival Study (4S)

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Case Study: 45-year-old Man

Baseline characteristics of HPS participants by prior diabetes

TNT Study: Baseline Characteristics of the Patients

The Hypertension in the Very Elderly Trial (HYVET)

Trial profile John A Dormandy et al. Lancet 2005;366:

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Advances in Hypertriglyceridemia Treatment

LRC-CPPT and MRFIT Content Points:

Volume 376, Issue 9753, Pages (November 2010)

Volume 378, Issue 9786, Pages (July 2011)

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Flow of Patients Through the Trial

Baseline Characteristics According to Sex

Trial profile Luc F Van Gaal, Lancet 2005;365:1389.

Flow of Patients Through Trial

Collet JP, et al. Lancet 2009;373:309-17

Characteristics of included studies

PROSPER: trial design

Baseline characteristics of the 1,842 men without coronary heart disease and the 230 men with a first coronary heart disease event during the 13-year.

The ACCORD Study Group. NEJM 2010; Epub March 14

FIELD: Primary outcome

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Trial profile The FIELD study investigators, Lancet Published online November 14, 2005

Baseline characteristics and medication The FIELD study investigators, Lancet Published online November 14, 2005

Plasma concentration of lipids at baseline and study close, with treatment group differences during follow-up The FIELD study investigators, Lancet Published online November 14, 2005

Kaplan-Meier curves of compliance with study medication (shown as time to permanent discontinuation) and cumulative risk curves of uptake of other lipid-lowering agents, by treatment group The FIELD study investigators, Lancet Published online November 14, 2005

Effect of treatment on primary and secondary outcomes The FIELD study investigators, Lancet Published online November 14, 2005

Cumulative risk curves of time to first events CHD=coronary heart disease. MI=myocardial infarction. CVD=cardiovascular disease. The FIELD study investigators, Lancet Published online November 14, 2005

Effect of fenofibrate treatment on total cardiovascular disease (CVD)events (CVD death,myocardial infarction,stroke,co ronary,or carotid revascularisation) * 102 cm for men >88 cm for women ‡Low HDL cholesterol plus high triglyceride The FIELD study investigators, Lancet Published online November 14, 2005

Patients on concominant medication between baseline and study close The FIELD study investigators, Lancet Published online November 14, 2005

Clinical and laboratory evidence of safety of fenofibrate The FIELD study investigators, Lancet Published online November 14, 2005